[go: up one dir, main page]

WO2023147092A3 - Coronavirus vaccine - Google Patents

Coronavirus vaccine Download PDF

Info

Publication number
WO2023147092A3
WO2023147092A3 PCT/US2023/011791 US2023011791W WO2023147092A3 WO 2023147092 A3 WO2023147092 A3 WO 2023147092A3 US 2023011791 W US2023011791 W US 2023011791W WO 2023147092 A3 WO2023147092 A3 WO 2023147092A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
disclosure relates
coronavirus
cov
sars
Prior art date
Application number
PCT/US2023/011791
Other languages
French (fr)
Other versions
WO2023147092A9 (en
WO2023147092A2 (en
Inventor
Ye Che
Kena Anne SWANSON
Original Assignee
BioNTech SE
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE, Pfizer Inc. filed Critical BioNTech SE
Priority to EP23708311.8A priority Critical patent/EP4469080A2/en
Priority to JP2024544699A priority patent/JP2025503994A/en
Publication of WO2023147092A2 publication Critical patent/WO2023147092A2/en
Publication of WO2023147092A3 publication Critical patent/WO2023147092A3/en
Publication of WO2023147092A9 publication Critical patent/WO2023147092A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
PCT/US2023/011791 2022-01-28 2023-01-27 Coronavirus vaccine WO2023147092A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP23708311.8A EP4469080A2 (en) 2022-01-28 2023-01-27 Coronavirus vaccine
JP2024544699A JP2025503994A (en) 2022-01-28 2023-01-27 Coronavirus vaccine

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202263304560P 2022-01-28 2022-01-28
US63/304,560 2022-01-28
US202263358523P 2022-07-05 2022-07-05
US63/358,523 2022-07-05
US202263396580P 2022-08-09 2022-08-09
US63/396,580 2022-08-09
US202363480375P 2023-01-18 2023-01-18
US63/480,375 2023-01-18

Publications (3)

Publication Number Publication Date
WO2023147092A2 WO2023147092A2 (en) 2023-08-03
WO2023147092A3 true WO2023147092A3 (en) 2023-08-31
WO2023147092A9 WO2023147092A9 (en) 2023-09-28

Family

ID=85415370

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2023/011791 WO2023147092A2 (en) 2022-01-28 2023-01-27 Coronavirus vaccine
PCT/US2023/011790 WO2023147091A1 (en) 2022-01-28 2023-01-27 Coronavirus vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2023/011790 WO2023147091A1 (en) 2022-01-28 2023-01-27 Coronavirus vaccine

Country Status (3)

Country Link
EP (1) EP4469080A2 (en)
JP (1) JP2025503994A (en)
WO (2) WO2023147092A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE059127T2 (en) 2015-10-22 2022-10-28 Modernatx Inc Respiratory virus vaccines
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
TW202417016A (en) * 2022-06-26 2024-05-01 德商拜恩技術股份公司 Coronavirus vaccine
WO2024050483A1 (en) * 2022-08-31 2024-03-07 Modernatx, Inc. Variant strain-based coronavirus vaccines and uses thereof
WO2025035187A1 (en) * 2023-08-15 2025-02-20 Macfarlane Burnet Institute For Medical Research And Public Health Limited Vaccine antigen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021188969A2 (en) * 2020-03-20 2021-09-23 Biontech Us Inc. Coronavirus vaccines and methods of use
WO2021243122A2 (en) * 2020-05-29 2021-12-02 Board Of Regents, The University Of Texas System Engineered coronavirus spike (s) protein and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
WO2017081082A2 (en) 2015-11-09 2017-05-18 Curevac Ag Optimized nucleic acid molecules
WO2018010822A1 (en) 2016-07-15 2018-01-18 Monocon International Refractories Limited Slag shield and method of occluding a tap channel
EP3424524B1 (en) 2017-07-04 2024-12-11 CureVac SE Cancer rna-vaccine
US11376320B2 (en) 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2
MX2021003199A (en) 2021-03-18 2022-09-19 Centro De Investig Y De Estudios Avanzados Del I P N Vaccines to prevent covid-19 based on non-glycosylated sites of the receptor binding domain (rbd) of the s protein of the sars-cov-2 virus.
MX2023003762A (en) 2021-04-12 2023-06-01 Academia Sinica Messenger rna vaccines against wide spectrum of coronavirus variants.
US20240293534A1 (en) 2021-06-14 2024-09-05 Modernatx, Inc. Coronavirus glycosylation variant vaccines
WO2022266010A1 (en) 2021-06-14 2022-12-22 Modernatx, Inc. Mrna vaccines encoding flexible coronavirus spike proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021188969A2 (en) * 2020-03-20 2021-09-23 Biontech Us Inc. Coronavirus vaccines and methods of use
WO2021243122A2 (en) * 2020-05-29 2021-12-02 Board Of Regents, The University Of Texas System Engineered coronavirus spike (s) protein and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAUDHARY NAMIT ET AL: "mRNA vaccines for infectious diseases: principles, delivery and clinical translation", NATURE REVIEWS DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 20, no. 11, 25 August 2021 (2021-08-25), pages 817 - 838, XP037602785, ISSN: 1474-1776, [retrieved on 20210825], DOI: 10.1038/S41573-021-00283-5 *
HSIEH CHING-LIN ET AL: "Structure-based design of prefusion-stabilized SARS-CoV-2 spikes", SCIENCE, vol. 369, no. 6510, 18 September 2020 (2020-09-18), US, pages 1501 - 1505, XP093044970, ISSN: 0036-8075, DOI: 10.1126/science.abd0826 *

Also Published As

Publication number Publication date
WO2023147092A9 (en) 2023-09-28
EP4469080A2 (en) 2024-12-04
WO2023147091A1 (en) 2023-08-03
WO2023147092A2 (en) 2023-08-03
JP2025503994A (en) 2025-02-06

Similar Documents

Publication Publication Date Title
EP4226938A3 (en) Coronavirus vaccine
WO2023147092A3 (en) Coronavirus vaccine
BR112022019781A2 (en) VACCINE FOR CORONAVIRUS
Blaauboer et al. The mucosal adjuvant cyclic di-GMP enhances antigen uptake and selectively activates pinocytosis-efficient cells in vivo
Coler et al. From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH‐F3+ GLA‐SE
McNeela et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery
Coler et al. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells
UY39060A (en) COMPOSITIONS AND METHODS TO PREVENT AND TREAT CORONAVIRUS INFECTION - SARS-COV-2 VACCINES
MX2023000411A (en) Sars-cov-2 and influenza combination vaccine.
Wang et al. Combined TLR7/8 and TLR9 ligands potentiate the activity of a Schistosoma japonicum DNA vaccine
EP4295862A3 (en) Coronavirus vaccine
EA201171032A1 (en) TREATMENT SCHEMES WITH THE HELP OF VACCINE AGAINST FLU, ASSOCIATED WITH PANDEMIC STRAINS
Stasiłojć et al. Recombinant Bacillus subtilis spores elicit Th1/Th17-polarized immune response in a murine model of Helicobacter pylori vaccination
Hou et al. The MSHA strain of Pseudomonas aeruginosa activated TLR pathway and enhanced HIV-1 DNA vaccine immunoreactivity
EA201391200A1 (en) METHODS AND COMPOSITIONS FOR VACCINATION FROM STAPHYLOCOCCUS AUREUS
MX2023000041A (en) Compositions and methods for inducing an immune response against coronavirus.
Kudyar et al. Periodontal vaccine: A dream or reality
BR112022016507A2 (en) VACCINES AGAINST CORONAVIRUS AND METHODS OF USE
MX2023012368A (en) Virus vaccine.
Bayih et al. DNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvant
Da’dara et al. Comparative efficacy of the Schistosoma mansoni nucleic acid vaccine, Sm23, following microseeding or gene gun delivery
Bolz et al. Use of recombinant virus replicon particles for vaccination against Mycobacterium ulcerans disease
RU2015106916A (en) CLOSTRIDIUM DIFFICILE POLYPEPTIDES AS A VACCINE
Kim et al. Efficacy of genotype-matched vaccine against re-emerging genotype V Japanese encephalitis virus
Shi et al. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23708311

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2024544699

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023708311

Country of ref document: EP

Effective date: 20240828